Results 31 to 40 of about 129,945 (312)

Defining the organizational structure of dopamine and muscarninic acetylcholine receptors [PDF]

, 2015
No abstract ...
Alvarez-Curto, Elisa, Caltabiano, Gianluigi Caltabiano, Liste, María José Varela, Marsango, Sara, Milligan, Graeme   +4 more
core   +1 more source

CXCR2 increases in ALS cortical neurons and its inhibition prevents motor neuron degeneration in vitro and improves neuromuscular function in SOD1G93A mice

Neurobiology of Disease, 2021
Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease characterized by depletion of motor neurons (MNs), for which effective medical treatments are still required.
Valentina La Cognata, Elisabetta Golini, Rosario Iemmolo, Sara Balletta, Giovanna Morello, Carla De Rosa, Ambra Villari, Sara Marinelli, Valentina Vacca, Gabriele Bonaventura, Paola Dell'Albani, Eleonora Aronica, Fabio Mammano, Silvia Mandillo, Sebastiano Cavallaro   +14 more
doaj   +1 more source

Investigation of ammonium–lauric salt as shale swelling inhibitor and a mechanism study

Adsorption Science & Technology, 2019
In this work, a series of ammonium–lauric salts (ALS) was prepared with lauric acid and amines as small molecular shale swelling inhibitor. The inhibitors were screened by the linear expansion test first, and the result shows that the inhibitor prepared ...
Jie Zhang, Weimin Hu, Li Zhang, Tiehu Li, Dan Cai, Gang Chen   +5 more
doaj   +1 more source

Edaravone: A new hope for patients with amyotrophic lateral sclerosis

Apollo Medicine, 2019
Although the exact pathophysiology of amyotrophic lateral sclerosis (ALS) remains unclear, oxidative stress is known to play a pivotal role. There is no cure for ALS, but there are two drugs available to slow the progression of the disease. Till recently,
Shivangi Garg, Dinesh Chaudhari, Pushpendra Nath Renjen, Anjali Mishra, Abhas Kumar, Rajendra Pradhan   +5 more
doaj   +1 more source

Bisperoxovanadium promotes motor neuron survival and neuromuscular innervation in amyotrophic lateral sclerosis

Molecular Brain, 2021
Amyotrophic lateral sclerosis (ALS) is the most common motor neuron (MN) disease, with no present cure. The progressive loss of MNs is the hallmark of ALS.
Junmei Wang, Lydia Tierney, Ranjeet Mann, Thomas Lonsway, Chandler L. Walker   +4 more
doaj   +1 more source

N-acetyl-l-tryptophan delays disease onset and extends survival in an amyotrophic lateral sclerosis transgenic mouse model

Neurobiology of Disease, 2015
Background: Whether l-NAT, a cytochrome c release inhibitor and an antagonist of NK-1R, provides protection in ALS is not known. Results: l-NAT delays disease onset and mortality in mSOD1G93A ALS mice by inhibiting mitochondrial cell death pathways ...
Wei Li, Anastasios Fotinos, Qiaofeng Wu, Yanchun Chen, Yongjin Zhu, Sergei Baranov, Yanyang Tu, Edward W. Zhou, Bharati Sinha, Bruce S. Kristal, Xin Wang   +10 more
doaj   +1 more source

The occurrence of herbicide-resistant Avena fatua (wild oats) populations to ACCase-inhibiting herbicides in Ireland

Irish Journal of Agricultural and Food Research, 2021
Following growers’ reports of herbicide control problems, populations of 30 wild oats, Avena fatua, were collected from the south-east main arable counties of Ireland in 2016 and investigated for the occurrence and potential for herbicide resistance to ...
R. Byrne, A.V. Vijaya Bhaskar, J. Spink, R. Freckleton, P. Neve, S. Barth   +5 more
doaj   +1 more source

Reaction-diffusion models for biological pattern formation [PDF]

, 2001
We consider the use of reaction-diffusion equations to model biological pattern formation and describe the derivation of the reaction-terms for several illustrative examples.
Crampin, E. J., Maini, P. K.
core   +1 more source

Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis

Acta Neuropathologica Communications, 2018
Amyotrophic lateral sclerosis (ALS) is a devastating and fatal motor neuron disease. Diagnosis typically occurs in the fifth decade of life and the disease progresses rapidly leading to death within ~ 2–5 years of symptomatic onset. There is no cure, and
L. McGurk, J. Mojsilovic-Petrovic, V. M. Van Deerlin, J. Shorter, R. G. Kalb, V. M. Lee, J. Q. Trojanowski, E. B. Lee, N. M. Bonini   +8 more
doaj   +1 more source

Management of imatinib-resistant CML patients [PDF]

, 2007
Imatinib has had marked impact on outcomes in chronic myelogenous leukemia (CML) patients for all stages of the disease and is endorsed by international treatment guidelines as the first line option.
Branford S, Burger H, Burgess MR, Cortes J, Crossman LC, Donato NJ, Druker BJ, Gambacorti-Passerini C, Giles F, Hochhaus A, Hughes TP, Iacobucci I, Kantarjian H, Lahaye T, Mahon FX, Melo JV, O'Hare T, Quintas-Cardama A, Rousselot P, Sleijfer S, Soverini S, Weisberg E   +21 more
core   +1 more source